CUDC-907: Preliminary Phase I data

Preliminary data from 11 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that oral CUDC-907 led to a partial response in 1

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE